DDInter387 DDInter1840
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Cisplatin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Cisplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Cisplatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Cisplatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Cisplatin (Compound) binds MT2A (Gene) and MT2A (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Cisplatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds SRC (Gene) and Crizotinib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Trabectedin (Compound)